Therapeutic potential of Toll-like receptor 9 activation (Q36501229)

14 August 2017

1 reference

title

Therapeutic potential of Toll-like receptor 9 activation (English)

1 reference

14 August 2017

0 references

1

Arthur M Krieg

1 reference

14 August 2017

1 June 2006

1 reference

Nature Reviews Drug Discovery

14 August 2017

1 reference

14 August 2017

5

1 reference

14 August 2017

471-484

1 reference

14 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2059

14 August 2017

0 references

cites work

Toll-like receptor control of the adaptive immune responses

1 reference

Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA.

31 March 2020

1 reference

A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA.

31 March 2020

1 reference

Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation

31 March 2020

1 reference

IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors

31 March 2020

1 reference

Toll-like receptors stimulate human neutrophil function

31 March 2020

1 reference

CpG DNA-mediated immune response in pulmonary endothelial cells

31 March 2020

1 reference

Microbial DNA induces a host defense reaction of human respiratory epithelial cells

31 March 2020

1 reference

Type I interferon dependence of plasmacytoid dendritic cell activation and migration.

31 March 2020

1 reference

CpG motifs in bacterial DNA and their immune effects

31 March 2020

1 reference

Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA.

31 March 2020

1 reference

Maintenance of serological memory by polyclonal activation of human memory B cells.

31 March 2020

1 reference

A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells

31 March 2020

1 reference

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.

31 March 2020

1 reference

Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help.

31 March 2020

1 reference

CpG motifs in bacterial DNA trigger direct B-cell activation

31 March 2020

1 reference

Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments

31 March 2020

1 reference

CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation

31 March 2020

1 reference

Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation

31 March 2020

1 reference

Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6.

31 March 2020

1 reference

Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88

31 March 2020

1 reference

IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling

31 March 2020

1 reference

The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6)

31 March 2020

1 reference

Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner.

31 March 2020

1 reference

Mechanism and function of a newly identified CpG DNA motif in human primary B cells

31 March 2020

1 reference

CpG ODN-mediated regulation of IL-12 p40 transcription

31 March 2020

1 reference

Toll-like receptor 9 signaling activates NF-kappaB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells

31 March 2020

1 reference

In vivo role of p38 mitogen-activated protein kinase in mediating the anti-inflammatory effects of CpG oligodeoxynucleotide in murine asthma

31 March 2020

1 reference

Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases

31 March 2020

1 reference

Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response

31 March 2020

1 reference

CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved

31 March 2020

1 reference

Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition

31 March 2020

1 reference

TLR9 signals after translocating from the ER to CpG DNA in the lysosome

31 March 2020

1 reference

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

31 March 2020

1 reference

The influence of base sequence on the immunological properties of defined oligonucleotides

31 March 2020

1 reference

Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides

31 March 2020

1 reference

Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation

31 March 2020

1 reference

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

31 March 2020

1 reference

The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets

31 March 2020

1 reference

Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction

31 March 2020

1 reference

Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs

31 March 2020

1 reference

P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides.

31 March 2020

1 reference

Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs

31 March 2020

1 reference

Effect of Suppressive DNA on CpG-Induced Immune Activation

31 March 2020

1 reference

CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation

31 March 2020

1 reference

Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions

31 March 2020

1 reference

Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus

31 March 2020

1 reference

Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma- and IL-12-mediated signaling.

31 March 2020

1 reference

Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells

31 March 2020

1 reference

Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist

31 March 2020

1 reference

Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice

31 March 2020

1 reference

Immune recognition of foreign DNA: a cure for bioterrorism?

31 March 2020

1 reference

CpG-DNA protects against a lethal orthopoxvirus infection in a murine model.

31 March 2020

1 reference

CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection

31 March 2020

1 reference

Oral pretreatment of mice with CpG DNA reduces susceptibility to oral or intraperitoneal challenge with virulent Listeria monocytogenes

31 March 2020

1 reference

Immunotherapeutic uses of CpG oligodeoxynucleotides

31 March 2020

1 reference

Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response

31 March 2020

1 reference

Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection

31 March 2020

1 reference

Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.

31 March 2020

1 reference

Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms

31 March 2020

1 reference

Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion

31 March 2020

1 reference

CpG oligodeoxynucleotides enhance host defense during murine tuberculosis

31 March 2020

1 reference

Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs

31 March 2020

1 reference

CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis

31 March 2020

1 reference

Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.

31 March 2020

1 reference

CpG-activated Thy1.2+ dendritic cells protect against lethal Listeria monocytogenes infection.

31 March 2020

1 reference

The adjuvant activity of CpG DNA requires T-bet expression in dendritic cells

31 March 2020

1 reference

Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge

31 March 2020

1 reference

Toll-like receptor signaling inhibits hepatitis B virus replication in vivo.

31 March 2020

1 reference

CpG Oligodeoxynucleotides Protect Normal and SIV-Infected Macaques from Leishmania Infection

31 March 2020

1 reference

Immunology of hepatitis B virus and hepatitis C virus infection

31 March 2020

1 reference

Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia

31 March 2020

1 reference

CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans

31 March 2020

1 reference

Toll-Like Receptor 2 (TLR2) and TLR9 Signaling Results in HIV-Long Terminal RepeatTrans-Activation and HIV Replication in HIV-1 Transgenic Mouse Spleen Cells: Implications of Simultaneous Activation of TLRs on HIV Replication

31 March 2020

1 reference

Was induction of HIV-1 through TLR9?

31 March 2020

1 reference

Endogenous IFN-alpha production by plasmacytoid dendritic cells exerts an antiviral effect on thymic HIV-1 infection

31 March 2020

1 reference

CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo

31 March 2020

1 reference

HIV-infected progressors and long-term non-progressors differ in their capacity to respond to an A-class CpG oligodeoxynucleotide

31 March 2020

1 reference

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

31 March 2020

1 reference

CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells

31 March 2020

1 reference

CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10.

31 March 2020

1 reference

CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses

31 March 2020

1 reference

Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins

31 March 2020

1 reference

Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity

31 March 2020

1 reference

Cysteine-tailed class I-binding peptides bind to CpG adjuvant and enhance primary CTL responses

31 March 2020

1 reference

Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.

31 March 2020

1 reference

CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity

31 March 2020

1 reference

CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants

31 March 2020

1 reference

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

31 March 2020

1 reference

CpG DNA induces stronger immune responses with less toxicity than other adjuvants

31 March 2020

1 reference

A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine

31 March 2020

1 reference

Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine

31 March 2020

1 reference

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice

31 March 2020

1 reference

Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies

31 March 2020

1 reference

Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12

31 March 2020

1 reference

T helper 2 immunity to hepatitis B surface antigen primed by gene-gun-mediated DNA vaccination can be shifted towards T helper 1 immunity by codelivery of CpG motif-containing oligodeoxynucleotides.

31 March 2020

1 reference

CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice

31 March 2020

1 reference

Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice

31 March 2020

1 reference

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

31 March 2020

1 reference

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

31 March 2020

1 reference

Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants

31 March 2020

1 reference

Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2

31 March 2020

1 reference

Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid

31 March 2020

1 reference

CpG DNA is an effective oral adjuvant to protein antigens in mice

31 March 2020

1 reference

Oral immunization with pBsVP6-transgenic alfalfa protects mice against rotavirus infection

31 March 2020

1 reference

Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant

31 March 2020

1 reference

Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection

31 March 2020

1 reference

Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge

31 March 2020

1 reference

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

31 March 2020

1 reference

A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant

31 March 2020

1 reference

Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response

31 March 2020

1 reference

CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice

31 March 2020

1 reference

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

31 March 2020

1 reference

CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma

31 March 2020

1 reference

Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA.

31 March 2020

1 reference

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

31 March 2020

1 reference

Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure

31 March 2020

1 reference

Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys

31 March 2020

1 reference

Perspectives in asthma: molecular use of microbial products in asthma prevention and treatment

31 March 2020

1 reference

Inhibition of experimental asthma by indoleamine 2,3-dioxygenase

31 March 2020

1 reference

Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides

31 March 2020

1 reference

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

31 March 2020

1 reference

Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.

31 March 2020

1 reference

CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma

31 March 2020

1 reference

Cellular immunity in breast cancer patients completing taxane treatment

31 March 2020

1 reference

Augmenting the potency of breast cancer vaccines: combined modality immunotherapy.

31 March 2020

1 reference

A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides

31 March 2020

1 reference

Synthetic oligonucleotides: the development of antisense therapeutics

31 March 2020

1 reference

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice

31 March 2020

1 reference

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

31 March 2020

1 reference

Toxicology of antisense therapeutics

31 March 2020

1 reference

Bacterial DNA causes septic shock

31 March 2020

1 reference

Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide

31 March 2020

1 reference

Inhibition of coagulation by a phosphorothioate oligonucleotide.

31 March 2020

1 reference

CpG DNA: a pathogenic factor in systemic lupus erythematosus?

31 March 2020

1 reference

Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB x NZWF1 mice

31 March 2020

1 reference

Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease

31 March 2020

1 reference

CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice

31 March 2020

1 reference

Immunostimulatory DNA sequences influence the course of adjuvant arthritis

31 March 2020

1 reference

Toll-like receptor 9-induced type I IFN protects mice from experimental colitis

31 March 2020

1 reference

Non-coding plasmid DNA induces IFN-gamma in vivo and suppresses autoimmune encephalomyelitis

31 March 2020

1 reference

Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity

31 March 2020

1 reference

Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.

31 March 2020

1 reference

Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling

31 March 2020

1 reference

CpG DNA induces cyclooxygenase-2 expression and prostaglandin production.

31 March 2020

1 reference

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy

31 March 2020

1 reference

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

31 March 2020

1 reference

Activation of autoreactive B cells by CpG dsDNA

31 March 2020

1 reference

Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes.

31 March 2020

1 reference

Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus

31 March 2020

1 reference

Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.

31 March 2020

1 reference

Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB × NZW mice

31 March 2020

1 reference

Suppressive oligonucleotides protect against collagen-induced arthritis in mice.

31 March 2020

1 reference

Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6

31 March 2020

1 reference

Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction

31 March 2020

1 reference

Myeloid differentiation factor 88-dependent post-transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: tumor necrosis factor-alpha receptor-associated factor 6, a diverging point in the Toll-like receptor 9-signaling

31 March 2020

1 reference

Myeloid differentiation factor 88-dependent transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: role of NF-kappaB and p38.

31 March 2020

1 reference

IRF-7 is the master regulator of type-I interferon-dependent immune responses

31 March 2020

1 reference

Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses

31 March 2020

1 reference

Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs.

31 March 2020

1 reference

Spontaneous Formation of Nucleic Acid-based Nanoparticles Is Responsible for High Interferon-α Induction by CpG-A in Plasmacytoid Dendritic Cells

31 March 2020

1 reference

Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells

31 March 2020

1 reference

A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production

31 March 2020

1 reference

Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells

31 March 2020

1 reference

Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions

31 March 2020

1 reference

Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation

31 March 2020

1 reference

CpG ODN enhances uptake of bacteria by mouse macrophages

31 March 2020

1 reference

Use of CpG oligodeoxynucleotides as immunoprotective agents

31 March 2020

1 reference

Quantification of Oligodeoxynucleotides in Human Plasma with a Novel Hybridization Assay Offers Greatly Enhanced Sensitivity over Capillary Gel Electrophoresis

31 March 2020

1 reference

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults

31 March 2020

1 reference

CpG DNA redirects class-switching towards "Th1-like" Ig isotype production via TLR9 and MyD88.

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2059

1 reference

PubMed ID

16763660

Dimensions Publication ID

14 August 2017

0 references

1 reference

PubMed ID

16763660